{"id":"NCT01444781","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants","officialTitle":"Evaluation of Antibody Persistence Following a Primary Series at 2, 4, and 6 Months on Trial A3L24 and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ Concomitantly Administered With Prevenar™ at 12 to 24 Months of Age in Healthy Latin American Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2013-04","completion":"2013-10","firstPosted":"2011-10-03","resultsPosted":"2014-07-16","lastUpdate":"2014-07-16"},"enrollment":1106,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Whooping Cough","Hepatitis B","Poliomyelitis"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide","otherNames":["DTaP-IPV-Hep B-PRP~T vaccine","Prevenar™"]},{"type":"BIOLOGICAL","name":"DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide","otherNames":["Infanrix hexa™","Prevenar™"]},{"type":"BIOLOGICAL","name":"DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine","otherNames":["DTaP-IPV-Hep B-PRP~T combined vaccine","Prevenar™"]}],"arms":[{"label":"Study Group 1","type":"EXPERIMENTAL"},{"label":"Study Group 2","type":"ACTIVE_COMPARATOR"},{"label":"Study Group 3","type":"EXPERIMENTAL"}],"summary":"This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722). The objectives are:\n\n* To describe the antibody persistence to any antigen contained in the investigational DTaP-IPV-Hep B-PRP-T vaccine and Infanrix hexa™ prior to the booster dose\n* To describe the safety and immunogenicity of the booster dose of either DTaP-IPV-Hep B-PRP-T or Infanrix hexa™ vaccine.\n* To describe the immunogenicity of a booster dose of Prevenar™ given at 12 to 24 months.","primaryOutcome":{"measure":"Summary of Diphtheria and Tetanus Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV Hep B-PRP T Vaccine or Infanrix Hexa Vaccine","timeFrame":"Day 140 (Primary series) and Day 0 (Pre-booster)","effectByArm":[{"arm":"Group 1: DTaP IPV Hep B PRP T + Prevenar™ Primary and Booster","deltaMin":392,"sd":null},{"arm":"Group 2DTaP IPV Hep B PRP T Primary/Infanrix Hexa+PCV7 Booster","deltaMin":391,"sd":null},{"arm":"Group 3Infanrix Hexa Primary/DTaP IPV Hep B PRP T+PCV7 Booster","deltaMin":259,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":2,"countries":["Colombia","Costa Rica"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":416},"commonTop":["Injection site Pain","Irritability","Crying","Anorexia","Drowsiness"]}}